Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting

Journal of the American College of Cardiology

Volumn 37, Issue 5, 2001, Pages 1323-1328

  Neumann, Franz Josef ^a   Hochholzer, Willibald ^a   Pogatsa Murray, Gisela ^a   Schömig, Albert ^a   Gawaz, Meinrad ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; EPTIFIBATIDE; THROMBIN; THROMBIN RECEPTOR; TIROFIBAN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BINDING SITE; BOLUS INJECTION; CHEMICAL STRUCTURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; STENTS; TYROSINE;

EID: 0035312338     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01165-2     Document Type: Article

References (34)

1. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
2. Glycoprotein IIb/IIIa receptor blockade with coronary stent placement
3. Platelet glycoprotein IIb/IIIa inhibitors: Basic and clinical aspects
4. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa
5. Abciximab (c7E3 Fab)
6. 7E3 Monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1
7. 3 integrins
8. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIa receptor
9. Design of potent and specific integrin antagonists
10. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
11. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction
12. Evaluation of platelet membrane glycoproteins in coronary artery disease: Consequences for diagnosis and therapy
13. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet glycoproteins after coronary stent placement
14. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess the safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
15. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
16. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
17. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure
18. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
19. Monitoring platelet GP IIb/IIIa antagonist therapy
20. Rapid platelet-function assay: An automated and quantitative cartridge-based method
21. The Accumetrics rapid platelet-function analyzer (RPFA) to monitor platelet aggregation during oral administration of a GP IIb/IIIa antagonist
22. Differential inhibition of platelet aggregation induced by adenosine diphosphate ora thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GP IIb/IIIa receptors
23. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): Flow and endocytic mechanisms contribute to the transport
24. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents
25. Use of a monodonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
26. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
27. A prospective multicenter study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary intervention
28. Novel dosing regimen of eptifibatide in planned coronary stent implantation: A randomized placebo-controlled trial
29. Increased neutrophil-platelet interaction in patients with unstable angina
30. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets
31. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GP IIb/IIIa receptor
32. 3 signaling and platelet function
33. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa inhibitors
34. Do tirofiban and ReoPro give similar efficacy outcomes trial